Patients with adverse events had significantly lower BMIs (21.1 vs 22.5, p=0.04), higher CAT scores (25.1 vs 22.3, p=0.01), lower MNA-SF scores (10.2 vs 11.8, p<0.001), higher rates of frailty (36% vs 21.3%, p=0.04), lower EPRs (70% vs 44.7% with EPR <0.755, p=0.002), higher rates of sarcopenia (50% vs 30%, p=0.01), and higher CRP levels (12.5 vs 7.8, p<0.001). This evidence concerns the gene CRP and sarcopenia.